Cargando…

Real-World Use of Loteprednol Etabonate 0.5%/Tobramycin 0.3% Ophthalmic Suspension for the Treatment of Ocular Surface Inflammatory Conditions

PURPOSE: Use of a combination corticosteroid/antibiotic product is common in ocular surface inflammatory conditions for which corticosteroid therapy is indicated and there exists a risk of superficial bacterial infection. Combination loteprednol etabonate 0.5% and tobramycin 0.3% (LE/T) has been eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Deom, James E, Kannarr, Shane, Vollmer, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677919/
https://www.ncbi.nlm.nih.gov/pubmed/36419563
http://dx.doi.org/10.2147/OPTH.S389688
_version_ 1784833895438483456
author Deom, James E
Kannarr, Shane
Vollmer, Patrick
author_facet Deom, James E
Kannarr, Shane
Vollmer, Patrick
author_sort Deom, James E
collection PubMed
description PURPOSE: Use of a combination corticosteroid/antibiotic product is common in ocular surface inflammatory conditions for which corticosteroid therapy is indicated and there exists a risk of superficial bacterial infection. Combination loteprednol etabonate 0.5% and tobramycin 0.3% (LE/T) has been evaluated for blepharokeratoconjunctivitis in two trials, but there has been limited reporting on its real-world use. PATIENTS AND METHODS: This was a retrospective chart review conducted at three optometry practices in the USA. Data were collected from cases in which LE/T was used and data were recorded for the period commencing with therapy with a minimum of one follow-up visit (within 2 months). Data abstracted included patient demographics, diagnosis, LE/T dosing regimen, pre- and post-treatment ocular signs and symptoms, intraocular pressure (IOP) measurements, adverse event (AE) reports, visual acuity (VA), and any notations as to resolution of baseline condition. Primary outcomes of interest included IOP changes and AEs. RESULTS: Ninety-six patient charts were extracted, and data from 87 charts (115 LE/T-treated eyes) were included. Mean (SD) years of age was 45.6 (19.7), most patients were white (83.9%), and just over half were female (58.6%). Common baseline conditions were conjunctival injury/corneal abrasion (25.3%), keratitis (18.4%), viral conjunctivitis (16.1%), and blepharitis/eyelid inflammation/MGD (11.5%). The most common LE/T dosing regimen was one drop QID. Mean (SD) IOP was 15.2 (4.4) mm Hg at baseline and 15.7 (4.4) mm Hg at the first follow-up visit (p = 0.2467). No AEs were recorded, and there were no significant changes in mean VA. Where recorded, most patients (83%) were noted as having their condition resolved/resolving at the first or second follow-up visit. CONCLUSION: LE/T appears to have a high level of safety when used for the management of various ocular surface inflammatory conditions encountered in optometric practice.
format Online
Article
Text
id pubmed-9677919
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-96779192022-11-22 Real-World Use of Loteprednol Etabonate 0.5%/Tobramycin 0.3% Ophthalmic Suspension for the Treatment of Ocular Surface Inflammatory Conditions Deom, James E Kannarr, Shane Vollmer, Patrick Clin Ophthalmol Short Report PURPOSE: Use of a combination corticosteroid/antibiotic product is common in ocular surface inflammatory conditions for which corticosteroid therapy is indicated and there exists a risk of superficial bacterial infection. Combination loteprednol etabonate 0.5% and tobramycin 0.3% (LE/T) has been evaluated for blepharokeratoconjunctivitis in two trials, but there has been limited reporting on its real-world use. PATIENTS AND METHODS: This was a retrospective chart review conducted at three optometry practices in the USA. Data were collected from cases in which LE/T was used and data were recorded for the period commencing with therapy with a minimum of one follow-up visit (within 2 months). Data abstracted included patient demographics, diagnosis, LE/T dosing regimen, pre- and post-treatment ocular signs and symptoms, intraocular pressure (IOP) measurements, adverse event (AE) reports, visual acuity (VA), and any notations as to resolution of baseline condition. Primary outcomes of interest included IOP changes and AEs. RESULTS: Ninety-six patient charts were extracted, and data from 87 charts (115 LE/T-treated eyes) were included. Mean (SD) years of age was 45.6 (19.7), most patients were white (83.9%), and just over half were female (58.6%). Common baseline conditions were conjunctival injury/corneal abrasion (25.3%), keratitis (18.4%), viral conjunctivitis (16.1%), and blepharitis/eyelid inflammation/MGD (11.5%). The most common LE/T dosing regimen was one drop QID. Mean (SD) IOP was 15.2 (4.4) mm Hg at baseline and 15.7 (4.4) mm Hg at the first follow-up visit (p = 0.2467). No AEs were recorded, and there were no significant changes in mean VA. Where recorded, most patients (83%) were noted as having their condition resolved/resolving at the first or second follow-up visit. CONCLUSION: LE/T appears to have a high level of safety when used for the management of various ocular surface inflammatory conditions encountered in optometric practice. Dove 2022-11-17 /pmc/articles/PMC9677919/ /pubmed/36419563 http://dx.doi.org/10.2147/OPTH.S389688 Text en © 2022 Deom et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Short Report
Deom, James E
Kannarr, Shane
Vollmer, Patrick
Real-World Use of Loteprednol Etabonate 0.5%/Tobramycin 0.3% Ophthalmic Suspension for the Treatment of Ocular Surface Inflammatory Conditions
title Real-World Use of Loteprednol Etabonate 0.5%/Tobramycin 0.3% Ophthalmic Suspension for the Treatment of Ocular Surface Inflammatory Conditions
title_full Real-World Use of Loteprednol Etabonate 0.5%/Tobramycin 0.3% Ophthalmic Suspension for the Treatment of Ocular Surface Inflammatory Conditions
title_fullStr Real-World Use of Loteprednol Etabonate 0.5%/Tobramycin 0.3% Ophthalmic Suspension for the Treatment of Ocular Surface Inflammatory Conditions
title_full_unstemmed Real-World Use of Loteprednol Etabonate 0.5%/Tobramycin 0.3% Ophthalmic Suspension for the Treatment of Ocular Surface Inflammatory Conditions
title_short Real-World Use of Loteprednol Etabonate 0.5%/Tobramycin 0.3% Ophthalmic Suspension for the Treatment of Ocular Surface Inflammatory Conditions
title_sort real-world use of loteprednol etabonate 0.5%/tobramycin 0.3% ophthalmic suspension for the treatment of ocular surface inflammatory conditions
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677919/
https://www.ncbi.nlm.nih.gov/pubmed/36419563
http://dx.doi.org/10.2147/OPTH.S389688
work_keys_str_mv AT deomjamese realworlduseofloteprednoletabonate05tobramycin03ophthalmicsuspensionforthetreatmentofocularsurfaceinflammatoryconditions
AT kannarrshane realworlduseofloteprednoletabonate05tobramycin03ophthalmicsuspensionforthetreatmentofocularsurfaceinflammatoryconditions
AT vollmerpatrick realworlduseofloteprednoletabonate05tobramycin03ophthalmicsuspensionforthetreatmentofocularsurfaceinflammatoryconditions